Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QPCT | Q16769 | 1/20 | 0.34 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15217037 | 1.00 | QPCT (0.34) | QPCTSLC29A1MEN1KMT2AMAOA | |
| SCHEMBL10034550 | 0.95 | QPCT (0.35) | QPCTMEN1KMT2AKCNH2HRH3 | |
| SCHEMBL28289028 | 0.95 | QPCT (0.35) | QPCTMEN1KMT2AKCNH2HRH3 | |
| SCHEMBL15108634 | 0.95 | QPCT (0.35) | QPCTMEN1KMT2AKCNH2HRH3 | |
| SCHEMBL25112162 | 0.88 | GBA1 (0.37) | QPCTMEN1KMT2AHTR2C | |
| SCHEMBL29323071 | 0.88 | GBA1 (0.37) | QPCTMEN1KMT2AHTR2C | |
| SCHEMBL27230179 | 0.88 | GBA1 (0.37) | QPCTMEN1KMT2AHTR2C | |
| SCHEMBL10034555 | 0.84 | QPCT (0.32) | QPCTHRH3 | |
| SCHEMBL10034554 | 0.84 | QPCT (0.32) | QPCTHRH3 | |
| SCHEMBL15217039 | 0.84 | QPCT (0.32) | QPCTHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8822448-B2 | Pyrazoloquinoline compound | ASTELLAS PHARMA INC. (JP) | 2014-09-02 | — | — | US | disclosed |
| US-8822448-B2 | Pyrazoloquinoline compound | ASTELLAS PHARMA INC. (JP) | 2014-09-02 | — | — | US | disclosed |
| US-20130225553-A1 | PYRAZOLOQUINOLINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-08-29 | — | — | US | disclosed |
| US-20130225553-A1 | PYRAZOLOQUINOLINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225553-A1 | PYRAZOLOQUINOLINE COMPOUND | PDE9A, PDE5A, PDE2A | QPCT 1757/4885SLC29A1 1076/4885MEN1 4011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.